Dr. Paradis has over 30 years' experience in both academies and global pharmaceutical industry with 16 years above focusing in rare disease. He obtined his MDCM from McGill University in Canada in 1981. He used to be clinical specialist on pediatrics and sub-specialty in gastroenterology, hepatology, liver transplantation and basic research on the origin of Kupffer cells in France, Canada and USA. He started his career in global pharmaceutical industry in 1996, He was head of EU clinical development in Genzyme overseeing approvals of Aldurazyme®, Myozyme®, Cerdelga® etc. 15 approvals (EU and US and other regions) in rare diseases and then became Global Head in rare genetic disease clinical development therapeutic area after Genzyme was acquired by Sanofi. He has been consulting start-ups in rare disease since 2017, including Spark, Erasmus University, Frazier Healthcare, Dynacure, Freeline, Prothelia etc.
address: A-216, No.56 Dongzhimen Wai Xie St. Chaoyang, Beijing 100027, China
tel: +86 10 6462 0528
address: Room 1502, Building C Poly West Bund Center, No.275, Ruiping Rd, Xuhui Disrict, Shanghai 200232, China